CATPB

CATPB
Identifiers
  • (3S)-3-[[2-(3-chlorophenyl)acetyl]amino]-4-[4-(trifluoromethyl)phenyl]butanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H17ClF3NO3
Molar mass399.79 g·mol−1
3D model (JSmol)
  • C1=CC(=CC(=C1)Cl)CC(=O)N[C@@H](CC2=CC=C(C=C2)C(F)(F)F)CC(=O)O
  • InChI=1S/C19H17ClF3NO3/c20-15-3-1-2-13(8-15)10-17(25)24-16(11-18(26)27)9-12-4-6-14(7-5-12)19(21,22)23/h1-8,16H,9-11H2,(H,24,25)(H,26,27)/t16-/m0/s1
  • Key:QOSIJVVNNGXEKE-INIZCTEOSA-N

CATPB is an experimental drug which acts as a potent and selective antagonist for the free fatty acid receptor FFAR2 (GPR43), and is used for research into the function of this receptor.[1][2][3][4][5][6]

References

  1. ^ Park BO, Kim SH, Kong GY, Kim DH, Kwon MS, Lee SU, et al. (January 2016). "Selective novel inverse agonists for human GPR43 augment GLP-1 secretion". European Journal of Pharmacology. 771: 1–9. doi:10.1016/j.ejphar.2015.12.010. PMID 26683635.
  2. ^ Mårtensson J, Holdfeldt A, Sundqvist M, Gabl M, Kenakin TP, Björkman L, et al. (December 2018). "Neutrophil priming that turns natural FFA2R agonists into potent activators of the superoxide generating NADPH-oxidase". Journal of Leukocyte Biology. 104 (6): 1117–1132. doi:10.1002/JLB.2A0318-130RR. PMID 30134499.
  3. ^ Højgaard Hansen A, Christensen HB, Pandey SK, Sergeev E, Valentini A, Dunlop J, et al. (November 2021). "Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2". ChemMedChem. 16 (21): 3326–3341. doi:10.1002/cmdc.202100356. PMID 34288488.
  4. ^ Miyasato S, Iwata K, Mura R, Nakamura S, Yanagida K, Shindou H, et al. (January 2023). "Constitutively active GPR43 is crucial for proper leukocyte differentiation". FASEB Journal. 37 (1): e22676. doi:10.1096/fj.202201591R. PMID 36468834.
  5. ^ Valentini A, Schultz-Knudsen K, Højgaard Hansen A, Tsakoumagkou A, Jenkins L, Christensen HB, et al. (May 2023). "Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists". Journal of Medicinal Chemistry. 66 (9): 6105–6121. doi:10.1021/acs.jmedchem.2c01935. PMC 10547238. PMID 37129317.
  6. ^ Muradás TC, Freitas RD, Gonçalves JI, Xavier FA, Marinowic DR (2024). "Potential antitumor effects of short-chain fatty acids in breast cancer models". American Journal of Cancer Research. 14 (5): 1999–2019. doi:10.62347/ETUQ6763. PMC 11162650. PMID 38859825.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.